NASDAQ:BWAY BrainsWay (BWAY) Stock Price, News & Analysis $7.95 +0.30 (+3.92%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$7.65▼$8.2550-Day Range$5.33▼$7.6552-Week Range$2.25▼$8.25Volume138,642 shsAverage Volume94,760 shsMarket Capitalization$132.53 millionP/E RatioN/ADividend YieldN/APrice Target$13.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends Get BrainsWay alerts: Email Address BrainsWay MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside63.5% Upside$13.00 Price TargetShort InterestHealthy0.24% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.61Based on 4 Articles This WeekInsider TradingN/AProj. Earnings Growth350.00%From $0.02 to $0.09 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.03 out of 5 starsMedical Sector403rd out of 936 stocksSurgical & Medical Instruments Industry51st out of 101 stocks 3.3 Analyst's Opinion Consensus RatingBrainsWay has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 2 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageBrainsWay has only been the subject of 2 research reports in the past 90 days.Read more about BrainsWay's stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.24% of the outstanding shares of BrainsWay have been sold short.Short Interest Ratio / Days to CoverBrainsWay has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in BrainsWay has recently increased by 8.26%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBrainsWay does not currently pay a dividend.Dividend GrowthBrainsWay does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BWAY. Previous Next 3.1 News and Social Media Coverage News SentimentBrainsWay has a news sentiment score of 0.61. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for BrainsWay this week, compared to 1 article on an average week.Search Interest5 people have searched for BWAY on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days.MarketBeat Follows4 people have added BrainsWay to their MarketBeat watchlist in the last 30 days. This is an increase of 300% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, BrainsWay insiders have not sold or bought any company stock.Percentage Held by Insiders19.00% of the stock of BrainsWay is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 30.11% of the stock of BrainsWay is held by institutions.Read more about BrainsWay's insider trading history. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for BrainsWay are expected to grow by 350.00% in the coming year, from $0.02 to $0.09 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of BrainsWay is -88.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of BrainsWay is -88.32, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBrainsWay has a P/B Ratio of 3.18. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about BrainsWay's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad DTIHow a $0.25 cent option contract makes my top traders feelIf you don’t know me, I’ve been in the markets for over 40 years… but recently, I’ve discovered a breakthrough that might be my favorite strategy of ALL time! While I kept the finer details of these $0.25 Cent Trades under wraps until recently…Click now to see for yourself what $0.25 Cent Trades is all about About BrainsWay Stock (NASDAQ:BWAY)BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.Read More BWAY Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BWAY Stock News HeadlinesJuly 26 at 1:12 AM | americanbankingnews.comBrainsWay (NASDAQ:BWAY) & Inspire Medical Systems (NYSE:INSP) Head-To-Head ComparisonJuly 23 at 8:00 AM | globenewswire.comBrainsWay to Report Second Quarter 2024 Financial Results on August 6, 2024July 26, 2024 | Awesomely, LLC (Ad)Automatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…July 16, 2024 | americanbankingnews.comComparing BrainsWay (NASDAQ:BWAY) & Profound Medical (NASDAQ:PROF)June 17, 2024 | globenewswire.comBrainsWay Expands Global Imprint with Exclusive Multi-Year Distribution Agreement in CanadaJune 11, 2024 | investorplace.comSmall-Cap Standouts: 3 Stocks Destined to Rule Their IndustriesJune 11, 2024 | investorplace.comSmall-Cap Standouts: 3 Stocks Destined to Rule Their IndustriesJune 10, 2024 | globenewswire.comBrainsWay Launches Prospective, Randomized, Controlled, Multicenter Trial Evaluating Accelerated Deep TMS™ for DepressionJuly 26, 2024 | Awesomely, LLC (Ad)Automatic Income (from home)Everyone’s talking about this new income hack that could generate triple digit returns on your money. But here’s the best part…June 3, 2024 | globenewswire.comBrainsWay Receives Expanded FDA Labeling to Treat Late Life DepressionMay 9, 2024 | seekingalpha.comBrainsWay: Cash Flows Are UnderappreciatedMay 8, 2024 | markets.businessinsider.comBWAY Stock Earnings: BrainsWay Beats Revenue for Q1 2024May 8, 2024 | globenewswire.comBrainsWay Reports First Quarter 2024 Financial Results and Operational HighlightsApril 24, 2024 | globenewswire.comBrainsWay to Report First Quarter 2024 Financial Results on May 8, 2024April 19, 2024 | stockhouse.comBrainsWay Expands Deep TMS(TM) Access in Israel Following Significant Increase in Reimbursement RatesApril 8, 2024 | msn.comOutset Medical stock rallies 22% as BTIG starts coverage at buyApril 6, 2024 | stockhouse.comBrainsWay Announces Published Review Results Highlighting Potential of Deep TMS(TM) to Treat Parkinson's DiseaseApril 5, 2024 | uk.investing.comBrainsWay Announces Published Review Results Highlighting Potential of Deep ™S™ to Treat Parkinson's DiseaseSee More Headlines Receive BWAY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for BrainsWay and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today7/26/2024Next Earnings (Confirmed)8/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Surgical & medical instruments Sub-IndustryN/A Current SymbolNASDAQ:BWAY CUSIPN/A CIK1505065 Webwww.brainsway.com Phone(722) 582-4030FaxN/AEmployees134Year FoundedN/APrice Target and Rating Average Stock Price Target$13.00 High Stock Price Target$15.00 Low Stock Price Target$11.00 Potential Upside/Downside+69.9%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.09) Trailing P/E RatioN/A Forward P/E Ratio382.50 P/E GrowthN/ANet Income$-4,200,000.00 Net Margins-4.83% Pretax Margin-4.10% Return on Equity-3.98% Return on Assets-2.68% Debt Debt-to-Equity RatioN/A Current Ratio4.48 Quick Ratio4.18 Sales & Book Value Annual Sales$31.78 million Price / Sales4.01 Cash FlowN/A Price / Cash FlowN/A Book Value$2.50 per share Price / Book3.06Miscellaneous Outstanding Shares16,670,000Free Float13,499,000Market Cap$127.53 million OptionableNot Optionable Beta1.24 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesMr. Hadar Levy (Age 50)Chief Executive Officer Comp: $434kMr. Avner Hagai (Age 68)Founder & Director Comp: $43.65kProf. Abraham Zangen (Age 54)Co-Founder, Member of Scientific Advisory Board & Director Comp: $72.17kDr. Yiftach Roth Ph.D. (Age 53)Founder & Chief Scientific Officer Comp: $108kMr. Ido Marom (Age 48)Chief Financial Officer Mr. Menachem C. Klein Esq.VP, General Counsel & Corporate SecretaryDr. Aron TendlerChief Medical OfficerMore ExecutivesKey CompetitorsBeyond AirNASDAQ:XAIRCerusNASDAQ:CERSSight SciencesNASDAQ:SGHTAnika TherapeuticsNASDAQ:ANIKNevroNYSE:NVROView All CompetitorsInstitutional OwnershipVirtu Financial LLCBought 11,273 shares on 5/20/2024Ownership: 0.068%Acadian Asset Management LLCBought 149,740 shares on 5/10/2024Ownership: 1.054%Essex Investment Management Co. LLCBought 88,593 shares on 5/3/2024Ownership: 1.952%View All Institutional Transactions BWAY Stock Analysis - Frequently Asked Questions How have BWAY shares performed this year? BrainsWay's stock was trading at $6.48 at the start of the year. Since then, BWAY shares have increased by 22.7% and is now trading at $7.95. View the best growth stocks for 2024 here. How were BrainsWay's earnings last quarter? BrainsWay Ltd. (NASDAQ:BWAY) announced its quarterly earnings results on Wednesday, May, 8th. The company reported $0.01 earnings per share for the quarter, topping analysts' consensus estimates of ($0.01) by $0.02. The firm had revenue of $9.10 million for the quarter, compared to analysts' expectations of $8.65 million. BrainsWay had a negative net margin of 4.83% and a negative trailing twelve-month return on equity of 3.98%. When did BrainsWay IPO? BrainsWay (BWAY) raised $30 million in an initial public offering (IPO) on Wednesday, April 17th 2019. The company issued 2,500,000 shares at $11.94 per share. Cantor served as the underwriter for the IPO. How do I buy shares of BrainsWay? Shares of BWAY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of BrainsWay own? Based on aggregate information from My MarketBeat watchlists, some other companies that BrainsWay investors own include AbbVie (ABBV), Advanced Micro Devices (AMD), Enterprise Products Partners (EPD), Pfizer (PFE), Neuronetics (STIM), Boingo Wireless (WIFI) and This page (NASDAQ:BWAY) was last updated on 7/26/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredWe recommended Nvidia in 2016, now we’re recommending this…The AI boom is just getting started. And the real wealth has still to be made…Porter & Company | SponsoredNEW AI developed by trader who won 1,129% (in 2 days)Earlier this year one legendary trader captured a 1,129% win (in just 2 days) ... LIVE in front of thousands o...Monument Traders Alliance | SponsoredBreaking News: Elon Musk Invents New Type of A.I. (Shocking)Could Elon's New Device be Bigger than the iPhone? According to 30-year Silicon Valley and Wall Street vete...InvestorPlace | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock (June 12) This $2 trillion D.C. shock i...Timothy Sykes | SponsoredGrab a pen and write down this ticker - here's whyA megatrend now poised to mint a brand-new wave of millionaires right here in America. And today, self-made...StocksToTrade | SponsoredBrace Yourself: Experts calling for Bitcoin to hit $100kFor the past few months, Bitcoin has been trading flat… It's been stuck around the $60,000 to $72,000 range...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding BrainsWay Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share BrainsWay With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
